IRIS
FABBIANI, MASSIMILIANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.113
EU - Europa 9.542
AS - Asia 6.434
SA - Sud America 1.308
Continente sconosciuto - Info sul continente non disponibili 843
AF - Africa 504
OC - Oceania 18
Totale 29.762
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.835
IT - Italia 3.185
RU - Federazione Russa 2.217
SG - Singapore 1.905
CN - Cina 1.580
BR - Brasile 1.082
GB - Regno Unito 934
IE - Irlanda 791
HK - Hong Kong 777
VN - Vietnam 754
DE - Germania 521
FR - Francia 432
KR - Corea 398
FI - Finlandia 335
SE - Svezia 311
ZA - Sudafrica 307
BD - Bangladesh 260
IN - India 240
UA - Ucraina 235
NL - Olanda 183
CA - Canada 138
ES - Italia 85
AR - Argentina 79
MX - Messico 77
IQ - Iraq 76
PL - Polonia 72
TR - Turchia 47
CI - Costa d'Avorio 45
ID - Indonesia 43
JP - Giappone 42
AT - Austria 41
KE - Kenya 37
IR - Iran 33
CO - Colombia 32
EC - Ecuador 31
CZ - Repubblica Ceca 30
NG - Nigeria 29
SA - Arabia Saudita 29
UZ - Uzbekistan 29
PK - Pakistan 26
MY - Malesia 25
EG - Egitto 24
VE - Venezuela 24
AE - Emirati Arabi Uniti 23
JO - Giordania 23
CH - Svizzera 22
BE - Belgio 21
LT - Lituania 18
PY - Paraguay 18
PH - Filippine 17
AU - Australia 16
MA - Marocco 16
CL - Cile 15
CR - Costa Rica 14
PE - Perù 13
PT - Portogallo 13
BG - Bulgaria 12
AL - Albania 11
IL - Israele 11
RO - Romania 11
AZ - Azerbaigian 9
TH - Thailandia 9
EE - Estonia 8
GT - Guatemala 8
LV - Lettonia 8
BH - Bahrain 7
DK - Danimarca 7
DO - Repubblica Dominicana 7
EU - Europa 7
NP - Nepal 7
SC - Seychelles 7
UY - Uruguay 7
BO - Bolivia 6
DZ - Algeria 6
ET - Etiopia 6
GE - Georgia 6
GR - Grecia 6
HR - Croazia 6
HU - Ungheria 6
JM - Giamaica 6
KZ - Kazakistan 6
OM - Oman 6
TN - Tunisia 6
TW - Taiwan 6
AO - Angola 5
CY - Cipro 5
LB - Libano 5
PA - Panama 5
PS - Palestinian Territory 5
SN - Senegal 5
TT - Trinidad e Tobago 5
BY - Bielorussia 4
HN - Honduras 4
KG - Kirghizistan 4
LK - Sri Lanka 4
MK - Macedonia 4
SV - El Salvador 4
AM - Armenia 3
NI - Nicaragua 3
SI - Slovenia 3
Totale 28.881
Salva come PNG Salva come JPEG
Città #
Dallas 3.256
Singapore 1.129
Milan 868
Dublin 776
Hong Kong 745
Ashburn 719
Southend 700
Moscow 697
San Jose 658
Hefei 551
Santa Clara 525
Fairfield 438
Chandler 394
Seoul 393
Council Bluffs 333
Siena 301
Los Angeles 300
Beijing 285
Johannesburg 285
Rome 263
Ho Chi Minh City 250
Munich 247
Woodbridge 241
Helsinki 229
Houston 214
Seattle 212
New York 185
Wilmington 173
Jacksonville 171
Florence 169
Lauterbourg 160
Hanoi 159
Cambridge 158
The Dalles 144
Ann Arbor 129
Princeton 110
São Paulo 98
Buffalo 90
Bengaluru 86
Chicago 85
Columbus 78
Nuremberg 65
Orem 64
Nanjing 54
Brescia 51
Frankfurt am Main 51
Boardman 48
Figino 48
London 47
Warsaw 46
Abidjan 45
Turku 44
Montreal 43
Redondo Beach 43
Naples 42
Shanghai 41
Menlo Park 40
Toronto 40
Dong Ket 39
Chennai 36
Rio de Janeiro 36
Tokyo 36
San Diego 35
Bologna 34
Düsseldorf 34
Lappeenranta 34
Brooklyn 33
Denver 31
Málaga 31
Turin 31
Haiphong 30
Baghdad 29
Da Nang 29
Mexico City 29
Atlanta 28
Portsmouth 27
Tashkent 27
Abuja 26
Stockholm 26
Paris 25
Phoenix 23
Amman 21
Brasília 21
Brussels 21
Shenyang 21
Washington 21
Amsterdam 20
Boston 20
Guangzhou 20
Miami 20
San Francisco 20
Vienna 20
Fremont 19
Mumbai 19
Nanchang 19
Curitiba 18
Newark 18
Piscataway 18
Poplar 17
Salt Lake City 17
Totale 18.895
Salva come PNG Salva come JPEG
Nome #
Compassionate use of meropenem/vaborbactam for infections caused by KPC-producing Klebsiella pneumoniae: a multicentre study 639
A first update on mapping the human genetic architecture of COVID-19 598
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population 590
A genome-wide association study for survival from a multi-centre European study identified variants associated with COVID-19 risk of death 530
Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study 508
Genetic mechanisms of critical illness in COVID-19 448
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males 435
An explainable model of host genetic interactions linked to COVID-19 severity 382
Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity 381
Extremely potent human monoclonal antibodies from COVID-19 convalescent patients 373
Pathogen-sugar interactions revealed by universal saturation transfer analysis 370
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 368
Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males 355
Colonizzazione e trapianto di polmone: il possibile ruolo dei colonizzanti multiresistenti sugli eventi infettivi in uno studio pilota osservazionale-retrospettivo 326
Peripheral biomarkers' panel for severe COVID-19 patients 322
null 320
Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research 318
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 311
Long Covid: analisi di casistica in follow-up a seguito di successive ondate epidemiche 310
Programma di vaccinazione antiMpox e screening infettivologico: opportunità di prevenzione in differenti categorie a rischio 309
B cell response after SARS-CoV-2 mRNA vaccination in people living with HIV 283
Strategie di vaccinazione anti-pneumococcica nel paziente adulto HIV-positivo: confronto fra vaccino coniugato 13-valente e vaccino polisaccaridico 23-valente 281
C9orf72 intermediate repeats confer genetic risk for severe covid-19 pneumonia independently of age 277
Evaluation and Optimization of an ELISA Procedure to Quantify Antibodies Against Pneumococcal Polysaccharides Included in the 13-Valent Conjugate Vaccine 275
Comparative determination of HIV-1 coreceptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping 259
Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes 257
Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility 249
Severe COVID-19 in hospitalized carriers of single CFTR pathogenic variants 248
Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality 246
Ultra-rare RTEL1 gene variants associate with acute severity of COVID-19 and evolution to pulmonary fibrosis as a specific long COVID disorder 226
Prevalence, Incidence and Predictors of Anal HPV Infection and HPV-Related Squamous Intraepithelial Lesions in a Cohort of People Living with HIV 223
B cell response six months after SARS-CoV-2 mRNA vaccination in people living with HIV under antiretroviral therapy 222
PATOGENI COLONIZZANTI IL NASOFARINGE DI SOGGETTI HIV POSITIVI E HIV NEGATIVI 216
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 215
Incidence and risk factors for respiratory tract bacterial colonization and infection in lung transplant recipients 214
WES profiling of COVID-19 214
Whole-genome sequencing reveals host factors underlying critical COVID-19 209
Antigenic sin and multiple breakthrough infections drive converging evolution of COVID-19 neutralizing responses 205
THE EFFECTS OF SWITCHING FROM DOLUTEGRAVIR/ABACAVIR/LAMIVUDINE TO BICTEGRAVIR/EMTRICITABINE/TENOFOVIR ALAFENAMIDE IN VIROLOGICALLY SUPPRESSED PEOPLE LIVING WITH HIV ON NEUROPSYCHIATRIC SYMPTOMS: PRELIMINARY FINDINGS FROM A RANDOMIZED STUDY 204
Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy 203
Clinical and molecular characterization of COVID-19 hospitalized patients 202
Protective role of a TMPRSS2 variant on severe COVID-19 outcome in young males and elderly women 201
Does Nirmatrelvir/Ritonavir Influence the Immune Response against SARS-CoV-2, Independently from Rebound? 199
Evidence of SARS-Cov-2-specific memory B cells six months after vaccination with BNT162b2 mRNA vaccine 199
Urinary tract infections caused by Gram-negative bacteria in elderly hospitalized patients: epidemiology, clinical features and outcomes in the era of antimicrobial resistance 195
Impact of hepatitis B vaccination in children born to HBsAg-positive mothers: a 20-year retrospective study 194
Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009 193
Colonizzazione da batteri multiresistenti nel trapianto di polmone ed eventi infettivi: studio pilota osservazionale-retrospettivo 192
Epidemiological and clinical study of viral respiratory tract infections in children from Italy 191
Does dual therapy have an impact on HIV-DNA decay in virologically-suppressed patients compared to triple therapy? Results from a multicentric study 191
B cell analyses after SARS-CoV-2 mRNA third vaccination reveals a hybrid immunity like antibody response 190
Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy 187
Peripheral lymphocyte subset monitoring in COVID-19 Italian patients 185
Staphylococcus aureus: studio clinico e microbiologico 185
Discordant liver fibrosis predictors in virologically suppressed people living with hiv without hepatitis virus infection 184
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 182
Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection 182
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients 180
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) 180
Comparison of HIV-1 Genotypic Resistance Test Interpretation Systems in virological outcomes over time 180
Polypharmacy, anticholinergic burden and drug-drug interaction assessment in people with four-class-resistant HIV: data from the PRESTIGIO registry 179
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis 178
Evidence of SARS-CoV-2-Specific Memory B Cells Six Months After Vaccination With the BNT162b2 mRNA Vaccine 177
Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine versus 23-Valent Polysaccharide Vaccine In HIV-Infected Adults 174
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 174
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 173
Host genetics and COVID-19 severity: increasing the accuracy of latest severity scores by Boolean quantum features 172
Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-naive individuals: Results from a European multi-cohort study 172
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort 171
Durability and liver safety of INSTI-based regimens in HIV-infected patients with advanced liver fibrosis or cirrhosis: data from the ODOACRE cohort 171
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study 168
Evolution of anal HPV infection and HPV-related squamous intraepithelial lesions in a cohort of PLWH: is there a benefit of HPV vaccination? 166
Patient profile characteristics when choosing different Dolutegravir-based dual therapies: impact on long term efficacy and durability 166
Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort 162
High prevalence of Hepatic Steatosis in a cohort of People Living With HIV: exploring the role of metabolic and HIV-related factors 161
Incidenza e fattori di rischio per colonizzazione ed infezione respiratoria batterica a 30 giorni in pazienti trapiantati di polmone 161
Longitudinal immunogenicity cohort study of SARS-CoV-2 mRNA vaccines across individuals with different immunocompromising conditions: heterogeneity in the immune response and crucial role of Omicron-adapted booster doses 160
Trajectory of Spike-Specific B Cells Elicited by Two Doses of BNT162b2 mRNA Vaccine 159
Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe 159
Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients 158
Trattamento efficace di osteomielite sternale con raccolta purulenta da Klebsiella pneumoniae multiresistente in recente trapianto di polmone 158
Retrospective study of tuberculosis in the Province of Siena [Studio retrospettivo sui ricoveri per tubercolosi nella provincia di Siena] 155
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 154
Vaccinazione anti SARSCov2 in una coorte di pazienti sottoposti a trapianto di cuore o di polmone: risposta umorale a dosi booster 152
Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients. 152
PRESTIGIO RING “a 59-year-old man with multidrug resistant HIV-1 infection failing a regimen including dolutegravir, rilpivirine, atazanavir/cobicistat: successful treatment tailoring based on genotypic and phenotypic resistance tests” 151
Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants 151
Homologous or heterologous administration of mRNA or adenovirus-vectored vaccines show comparable immunogenicity and effectiveness against the SARS-CoV-2 Omicron variant 150
Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction 150
Human bocavirus detection in an atopic child affected by pneumonia associated with wheezing 146
Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO Registry 145
Is there a drug-drug interaction between darunavir/ritonavir and raltegravir? 144
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients 142
A challenging case of SARS-CoV-2- AIDS and Nocardiosis coinfection from the SMatteo COvid19 REgistry (SMACORE) 140
Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia 140
Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen 140
Poor concordance between liver stiffness and non-invasive fibrosis scores in HIV-1 monoinfected virologically suppressed patient 139
Outcomes and Predictors of Mortality in Patients With KPC-Kp Infections Treated With Meropenem Vaborbactam: An Observational Multicenter Study 138
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 138
Prevalence and correlates of Hepatic Steatosis and Metabolic-associated Fatty Liver Disease in a cohort of People Living With HIV 137
Totale 22.994
Salva come PNG Salva come JPEG
Categoria #
all - tutte 89.797
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 89.797
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.011 0 100 43 59 67 54 56 59 87 86 151 249
2022/20231.669 101 153 173 201 135 309 115 158 142 59 74 49
2023/20241.504 72 45 167 93 72 344 436 67 15 44 56 93
2024/20256.115 171 175 388 238 895 367 564 364 450 306 536 1.661
2025/202615.462 1.015 2.289 2.618 1.781 2.228 508 1.580 543 566 781 601 952
2026/2027908 854 54 0 0 0 0 0 0 0 0 0 0
Totale 29.762